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Proliferative capacity of vein graft smooth muscle
cells and fibroblasts in vitro correlates with graft
stenosis
Richard D. Kenagy, PhD, Nozomi Fukai, MD, PhD, Seung-Kee Min, MD,* Florencia Jalikis, MD,
Ted R. Kohler, MD, and Alexander W. Clowes, MD, Seattle, Wash
Objective: About a quarter of peripheral vein grafts fail due in part to intimal hyperplasia. The proliferative capacity and
response to growth inhibitors of medial smooth muscle cells and adventitial fibroblasts in vitro were studied to test the
hypothesis that intrinsic differences in cells of vein grafts are associated with graft failure.
Methods:Cells were grown from explants of the medial and adventitial layers of samples of vein grafts obtained at the time
of implantation. Vein graft patency and function were monitored over the first 12 months using ankle pressures and
Duplex ultrasound to determine vein graft status. Cells were obtained from veins from 11 patients whose grafts remained
patent (non-stenotic) and from seven patients whose grafts developed stenosis. Smooth muscle cells (SMCs) derived from
media and fibroblasts derived from adventitia were growth arrested in serum-freemedium and then stimulated with 1M
sphingosine-1-phosphate (S1P), 10 nM thrombin, 10 ng/ml epidermal growth factor (EGF), 10 ng/ml platelet-derived
growth factor-BB (PDGF-BB), PDGF-BB plus S1P, or PDGF-BB plus thrombin for determination of incorporation of
[3H]-thymidine into DNA. Cells receiving PDGF-BB or thrombin were also treated with or without 100g/ml heparin,
which is a growth inhibitor. Cells receiving thrombin were also treated with or without 150 nM AG1478, an EGF
receptor kinase inhibitor.
Results: SMCs and fibroblasts from veins of patients that developed stenosis responded more to the growth factors, such
as PDGF-BB alone or in combination with thrombin or S1P, than cells from veins of patients that remained patent (P 
.012). In addition, while PDGF-BB-mediated proliferation of fibroblasts from grafts that remained patent was inhibited
by heparin (P< .03), PDGF-BB-mediated proliferation of fibroblasts from veins that developed stenosis was not (P> .5).
Conclusion: Inherent differences in the proliferative response of vein graft cells to PDGF-BB and heparin may explain, in
part, the variability among patients regarding long term patency of vein grafts. ( J Vasc Surg 2009;49:1282-8.)
Clinical Relevance: The reason why peripheral venous bypass graft stenosis occurs in about one-quarter of patients is
unclear. We have cultured cells from veins obtained at the time of graft placement and using these have confirmed the
hypothesis that cells from vein grafts that develop stenosis are inherently more responsive to growth factors (eg,
platelet-derived growth factor) and less sensitive to growth inhibitors (eg, heparin). These data suggest a role for
platelet-derived growth factor in vein graft stenosis, thus supporting further study of this growth factor as a possible
therapeutic target for this clinical problem.Autogenous saphenous vein remains the preferred con-
duit for lower extremity arterial bypass. Despite improved
surgical techniques and careful postoperative surveillance,
hemodynamically significant stenosis continues to affect
about one-quarter of all peripheral vein grafts during the
first year after implantation.1 While a large literature exists
on the response of arteries to injury, relatively little is
known about the response of veins to implantation in the
arterial circulation. Animal models show a rapid loss of cells
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1282in the media due to death2 followed by thickening of the
intimal andmedial layers of the vein as a consequence of cell
migration from medial and adventitial layers and the inva-
sion of progenitor cells from the blood,3,4 coupled with cell
proliferation and deposition of extracellular matrix (re-
view5). However, these vein grafts in animals do not de-
velop stenosis. In humans, smooth muscle cell (SMC)
proliferation6 and deposition of extracellular matrix7 con-
tribute to intimal thickening and luminal stenosis. The
advanced vein graft lesions, like the injury-induced lesions
in animal arteries, are composed primarily of matrix.7,8
Recent observations indicate that both intimal hyperplasia
and vessel remodeling play a role in the loss of luminal
area,9,10 similar to the response of diseased arteries to
angioplasty.11
Little is known about why most grafts preserve their
lumen while one-quarter develop focal or diffuse stenosis.
The usual cardiovascular risk factors fail to predict periph-
eral vein graft failure, although smoking has sometimes
been reported to be a risk factor for peripheral vein graft
stenosis.12-14 Vein morphology preimplantation does not
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by duplex scanning may identify sites of predilection.12 It is
possible that there are either systemic (eg, blood borne) or
local factors that control the vein SMC response to injury.15
In addition, there is some evidence that certain patients are
predisposed to vein graft stenosis. For example, stenosis in
a graft in one leg predicts stenosis in a graft placed in the
opposite leg.16 Differences among mouse strains in the res-
ponse to wire injury and vein grafting also support the
possibility of genetic differences in susceptibility to vein
graft hyperplasia.17 Of particular interest are the studies of
Chan and colleagues on human vein SMCs that provide an
intriguing link between heparin responsiveness and vein
graft patency.18,19 Vein graft stenosis is correlated with a
loss of heparin sensitivity. Aortic SMCs, and possibly vein
graft cells, utilize the heparin binding growth factors, fibro-
blast growth factor2 (FGF2) and heparin-binding EGF-like
growth factor (HB-EGF), in an autocrine/paracrine man-
ner for platelet-derived growth factor (PDGF)-BB and
thrombin growth stimulation.20,21 Together, these data
suggest a possible difference in the utilization of heparin-
binding growth factors by SMCs from stenotic patients. It
is clear that endogenous heparan sulfate proteoglycans can
retard as well as promote SMC growth in vivo.22-25 There-
fore, we think that variability in heparin responsiveness
might be accounted for by variable use of the heparin-
sensitive co-stimulatory pathways.
In this study, we investigated the hypothesis that lumi-
nal narrowing in vein grafts may be explained by the vein
graft cells themselves, which may be hyper responsive to
growth stimulants or may lack pathways designed to shut
off growth. In particular, we have studied the response to
the growth factors PDGF, thrombin, and sphingosine-1-
phosphate (S1P), which are known to play critical roles in
the response to vascular injury and atherosclerosis,26-28 and
to inhibitors of the heparin-binding growth factors, FGF2
and HB-EGF.
MATERIALS AND METHODS
Materials. Platelet-derived growth factor-BB (PDGF-
BB) was purchased from R&D Systems (Minneapolis,
Minn). Thrombin was from American Diagnostica (Green-
wich, Conn) and sphingosine-1-phosphate (S1P) was from
Cayman Chemical (Ann Arbor, Mich). AG 1478 was ob-
tained from Calbiochem (Gibbstown, NJ) and 3H-thymi-
dine was obtained from Perkin-Elmer Life Sciences (Bos-
ton, Mass). Epidermal growth factor (EGF) and heparin
(porcine intestinal) were from Sigma-Aldrich (St Louis,
Mo). All cell culture solutions were purchased from In-
vitrogen Corporation (Carlsbad, Calif).
Cell culture and proliferation. Segments of human
saphenous vein were harvested at the time of bypass under
a protocol approved by the University of Washington and
Puget Sound Veterans Administration Human Subjects
review board. The endothelium was wiped off and the
media and adventitia were separated. Explants of media and
adventitia were cultured in Dulbecco’s minimal essential
media supplemented with 20% fetal bovine serum (DMEM20%). Cells began migrating out of explants after two to
four days and were first passaged between two and four
weeks. After the first passage, medial cells were maintained
in 20% serum, while adventitial cells were maintained in
15% serum to maintain approximately equal doubling
times. Cells between passages five and nine were used for
experiments. Cells were seeded at 20,000 cm2 overnight in
DMEMwith 20% serum (medial cells) or DMEMwith 15%
serum (adventitial cells) and then switched to serum-free
DMEM for 24 hours. Medium was then changed again
with serum-free medium and after another 48 hours agents
were added directly as follows: PDGF-BB 10 ng/ml 100
g/ml heparin; 10 nM Thrombin 100 g/ml hepa-
rin; 10 nM Thrombin  0.15 M AG1478; 1 M S1P;
PDGF-BB 10 ng/ml  10 nM Thrombin ; PDGF-BB 10
ng/ml 1 MS1P; and 10 ng EGF 0.15 MAG1478.
DMSO was used as a control for AG1478. After 20 hours,
0.5 Ci/ml 3H-thymidine was added and incubated for
another eight hours at which time cells were harvested and
incorporation of 3H-thymidine into DNA was determined
as previously described.29
Patient population and postoperative surveillance.
Male and female patients scheduled for lower extremity
bypass using vein grafts were eligible for this study. Patients
were excluded if they were unable to return for follow-up
examinations, unable to give informed consent, or if they
developed acute vein graft failure (less than onemonth). All
patients received saphenous vein grafts except for one pa-
tient each in the stenotic and non-stenotic groups that
received arm vein-saphenous vein composite grafts (the
stenosis occurred in the proximal saphenous vein portion of
the composite graft). Other patient demographics for the
11 non-stenotic and seven stenotic patients are listed in the
Table. Not all patients’cells were used in all experiments.
All patients were followed for 12 months with ankle
pressures and Duplex ultrasound. Examinations were
carried out during surgery, at 6 weeks and at 3, 6, 9, and
12 months after surgery. Vein graft stenosis was defined
as significant if the peak systolic velocity was greater than
300 cm/s and the ratio of the peak systolic velocities in
adjacent segments exceeded 3.0. Additional duplex ex-
aminations were performed if a drop in the ankle-arm
index of at least 0.15 was noted or symptoms returned.
At 12 months after the surgery, the graft status of each
patient was disclosed to the investigators performing the
in vitro experiments.
Statistical analysis. Experiments for each cell line
were performed in triplicate and were repeated two to six
times. All combined data were analyzed by analysis of
variance using the SPSS (Chicago, Ill) 8.0 GM General
Factorial method with growth factor treatment, cell type,
and vein graft status as factors; age of the patient as a
covariate; and the experiment number as a weighted least
squares variable. Comparisons of two groups were per-
formed using the Mann-Whitney or Wilcoxon’s signed
rank tests or the paired t test as appropriate.
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By multivariate analysis, DNA synthesis in response to
growth factors was significantly increased in cells from
patients that developed vein graft stenosis compared with
those that did not develop stenosis (P  .0005). In addi-
tion, fibroblasts were more responsive than SMCs (P 
.0005). Neither age (P  .128) nor gender (P  .252)
significantly affected DNA synthesis. The proliferative re-
sponse of cultured medial and adventitial cells to specific
growth factors is presented in Fig 1 in which proliferation is
expressed as fold of serum-starved control for cells from
veins that go on to stenosis compared with those that do
not. Basal DNA synthesis of serum-starved cells was not
significantly different among the groups (1048349, 787
183, 850  172, and 667  128 cpm for non-stenotic
SMCs, stenotic SMCs, non-stenotic fibroblasts, and ste-
notic fibroblasts, respectively; mean SEM; N 10, 6, 9,
and 6, respectively). Both SMCs (Fig 1, A) and fibroblasts
(Fig 1, B) responded more to PDGF-BB than to EGF,
S-1-P, or thrombin, but the combination of PDGF-BB
with either thrombin or S-1-P gave an additive effect.
Comparing SMCs and fibroblasts from the same patient,
PDGF-BB increased fibroblast and SMC proliferation by
21.4  3.7- and 12.5  1.8-fold of control, respectively
(mean  SEM; 12 paired cell lines; P  .0148). There was
no significant correlation between DNA synthesis and cell
passage number (data not shown). Finally, we did not find
any difference between first passage times of cells after
explanting tissue from veins of patients with patent grafts
Table. Patient demographics
Non stenotic (11) Stenotic (7)
Male/Female 11/0 6/1
Age (years) 65.0  2.6 71.7  3.2
Race
White 10 7
Afro-American 1 0
Comorbidities
Hypertension 10 6
Diabetes 4 4
Renal insufficiency 3 0
Tobacco use
Current 8 1
Ex 2 5
Never 1 1
Dyslipidemia 6 5
CAD 6 3
CVD 0 1
Clinical indication
Gangrene 3 1
Ulcer 3 2
Resting pain 2 1
Claudication 3 3
Anatomic configuration
Femoro-popliteal 5 5
Femoro-tibial 6 2
Prior vein graft stenosis 1 2
CAD, Coronary artery disease; CVD, Cerebrovascular disease.compared with those with stenotic grafts (19.9  1.2 vs.21.2 2.4 days, respectively; mean SEM; P .639) nor
did we find any significant correlation between DNA syn-
thesis and time to first passage (data not shown).
Heparin significantly inhibited PDGF-BB-mediated
proliferation of venous SMCs and fibroblasts from veins of
non-stenotic patients and of SMCs from veins that became
stenotic by 21, 10, and 17%, respectively (P  .036 , .036,
and .011, respectively; Fig 2, A). In contrast, fibroblasts
from veins that became stenotic were not significantly
inhibited by heparin when stimulated by PDGF-BB (P 
.238; Fig 2, A). There was no correlation between heparin
sensitivity and age of cell donor (P  .974). Thrombin-
induced proliferation of all types of cells was inhibited by
more than 40% by heparin (P  .05; Fig 2, B). SMCs
tended to have greater sensitivity to heparin than fibroblasts
(P  .027 for PDGF and P  .0785 for thrombin with 14
paired SMCs and fibroblasts). Finally, regarding the inhib-
itory effect of the EGF receptor kinase inhibitor AG1478
on thrombin-mediated proliferation, there were no signif-
icant differences between SMCs from veins that became
stenotic compared with those from veins that remained
patent (56.4  11.5% and 58.1  9.5% inhibition, respec-
tively; mean SEM, N 8-10; P .1) or fibroblasts from
non-stenotic and stenotic grafts (44.0  5.9% and 53.5 
5.9% inhibition, respectively; N  5-10; P  .1).
DISCUSSION
We have observed that cells obtained from the adven-
titia and media of saphenous veins from patients whose
femoro-popliteal or femoro-tibial grafts go on to stenose
proliferate faster than those obtained from the veins of
patients with non-stenotic grafts. This property of the cells
may partially explain stenosis of the vein grafts of these
patients. Because SMCs from restenotic arterial lesions
have been shown to proliferate faster than those from
primary arterial lesions,30 it should be emphasized that the
cells used in our experiments were obtained from normal
venous tissue obtained at the time of grafting, not from
stenotic or non-stenotic arterialized vein grafts. Aortocoro-
nary grafts fashioned from internal mammary artery or
radial artery are much more durable than saphenous vein
grafts,31 and it is of note that SMCs derived from internal
mammary artery proliferate less than SMCs from saphenous
vein.32 Thus, the proliferative capacity of SMCs in culture
may be predictive of graft stenosis. Although there are a
number of possible explanations, differences in SMC func-
tion and gene expression might account for the differences
in graft performance. For example, it is known that the
internal mammary artery is more resistant to atherosclerosis
than the coronary artery, and this difference is reflected in
the molecular phenotype of the cultured SMCs.33 In organ
culture, veins exhibit increased synthesis of extracellular
matrix proteins, such as versican, compared with arteries.34
SMCs from aorta express the protein, regulator of G pro-
tein signaling 5 (RGS5), while SMCs from vena cava,
coronary artery, and intimal hyperplastic lesions in cyno-
molgous monkey grafts do not.35-37 RGS5 is an inhibitor
of Gi and Gq activation and therefore may play a role in
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obtained from saphenous vein have higher levels of PDGF
receptor  and proliferate about two-fold faster in response
to PDGF than do those from internal mammary artery.38
These differences are comparable to the differences we have
observed between strains of cells from vein grafts that
remain patent or eventually develop stenosis. While these
may appear to be modest differences in growth rate, they
may be sufficient given that lesion growth in vivo in vein
Fig 1. DNA synthesis in reponse to growth factors by
from veins that developed stenosis (open bars) compared
mean  SEM of fold of control values of 3H-thymidi
factors. Values for N are indicated within the bars.
Fig 2. Effect of heparin (100 g/ml) on PDGF-BB- m
PDGF-BB plus heparin vs. PDGF-BB alone) and on th
comparing thrombin plus heparin vs. thrombin alone).
indicated in the bars.grafts appears to take months.39,40 Whether differences inPDGF receptor levels exist between SMCs of veins from
patients that develop graft stenosis and SMCs from veins of
patients with patent grafts is not known. In this regard, the
observations of Conte and colleagues that C-reactive pro-
tein increases PDGF receptor  levels in cultured saphe-
nous vein SMCs and that C-reactive protein levels may be
correlated with graft outcome in vivo are intriguing.15,41
We have also demonstrated that PDGF-mediated pro-
liferation of fibroblasts from vein grafts that do not develop
nous vein smooth muscle cells (A) and fibroblasts (B)
veins that remained patent (closed bars). Values are the
corporation after treatment with the indicated growth
d 3H-thymidine incorporation (A; *P .05 comparing
in-mediated 3H-thymidine incorporation (B; *P  .05
smooth muscle cells; Fibs: fibroblasts; values for N aresaphe
with
ne inediate
romb
SMC:stenosis are sensitive to heparin, while fibroblasts from
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the work by Chan and colleagues, who showed that venous
SMCs from grafts that develop stenosis are less responsive
to the growth inhibitory effects of heparin.18,19 There are
two important aspects of our data regarding heparin.
First, there are some differences between the present work
and that of Chan and coworkers. In the present study, only
adventitial fibroblasts were less responsive to heparin. Chan
and colleagues found that medial SMCs from the stenotic
grafts were less sensitive, but they did not study adventitial
cell responsiveness. The potential importance of our obser-
vation with fibroblasts is underlined by differences between
fibroblasts and SMCs. Adventitial fibroblasts proliferate
faster than the SMCs. This is important given reports that
in rat and pig vein grafts medial cells die in response to
exposure to arterial pressure and migrating adventitial cells
repopulate the medial and intimal layers.4,42 It is possible
that human vein grafts heal in the same way. It may be of
great relevance to vein graft failure that fibroblasts have a
greater proliferative response and that fibroblasts from ste-
notic patients are insensitive to heparin. A second point
regarding heparin relates to possible mechanisms for the
inhibitory effect of heparin. There is a clear inverse relation-
ship between the extent of proliferation and heparin sensi-
tivity, which suggests the possibility that the high level of
proliferation in some of these cell lines that are insensitive
to heparin comes about from the autocrine release of
heparin insensitive, EGF receptor-binding growth factors,
such as epiregulin or betacellulin.43 Our results show that
thrombin-mediated proliferation is inhibited by the EGF
receptor kinase inhibitor, AG1478, in these heparin insen-
sitive cell lines (data not presented). We have shown that
FGF2, a heparin binding growth factor, is released by
PDGF-BB and thrombin and acts as an autocrine co-
stimulator of human arterial SMC proliferation.20,21 Hep-
arin binding EGF-like growth factor (HB-EGF) is released
by thrombin to increase migration of rat arterial SMCs.44
In each case, heparin blocks either SMC proliferation or
migration by interfering with the released heparin binding
growth factor. Our studies suggest that heparin-sensitive
human venous cells may release heparin-binding growth
factors in response to PDGF-BB and thrombin.
The role of PDGF in vein graft stenosis is not clear, but
there are several reasons to suggest it is important. First, we
observed that there is a differential response to PDGF-BB
in cells from stenotic compared with non-stenotic vein
grafts. PDGF-BB has been found in normal human saphe-
nous veins,45 the levels of PDGF correlate with intimal
hyperplasia in a rodent vein graft model,46,47 and blockade
of PDGF prevents intima formation in human saphenous
vein organ culture.48 Of particular interest, levels of PDGF
decline in arterialized vein grafts undergoing atrophy after
re-implantation in the venous circulation.46 We have
shown that blockade of the PDGF receptors  and  causes
neointimal regression in synthetic arterial grafts without
affecting the adjacent normal arteries.49 The tyrosine kinase
inhibitor Gleevec, which inhibits PDGF receptor kinase
activity, causes regression of pulmonary artery wall thicken-ing in animals with pulmonary hypertension and was re-
ported to normalize symptoms of idiopathic pulmonary
hypertension in two human case studies.50-52 In summary,
the results of these studies support the conclusion that
PDGF is required not only to drive growth of the intima,
but also to prevent regression of established thickening. If
this conclusion is correct, then pharmacological blockade
of the PDGF pathway might prevent stenosis or restore an
adequate lumen by inducing intimal atrophy.53 Additional
studies are required to determine if specific components of
the PDGFR signaling pathway are different in cells from
patients that will develop graft stenosis compared with
those that do not. If this is found to be the case, it is possible
that screening of venous tissue at the time of grafting might
identify those patients requiring more stringent follow up
care.
Limitations of this study are primarily related to small
sample size. Because we did not critically limit the time
between removal of the vein from the patient and explant
culture, it is possible that ex vivo injury affected outcome of
the in vitro experiments. However, we did not find any
correlation between response to growth factors and the
time to first passage of cells in culture.
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